Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase (NAMPT), have been developed over the past two decades. However, their limited anti-cancer...
-
2022 (v1)PublicationUploaded on: February 4, 2024
-
2023 (v1)Publication
No description
Uploaded on: February 4, 2024 -
2023 (v1)Publication
: Identifying oncological applications for drugs that are already approved for other medical indications is considered a possible solution for the increasing costs of cancer treatment. Under the hypothesis that nutritional stress through fasting might enhance the antitumour properties of at least some non-oncological agents, by screening drug...
Uploaded on: February 4, 2024 -
2021 (v1)PublicationSIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice
Sirtuin 6 (SIRT6) is a NAD+-dependent deacetylase with key roles in cell metabolism. High SIRT6 expression is associated with adverse prognosis in breast cancer (BC) patients. However, the mechanisms through which SIRT6 exerts its pro-oncogenic effects in BC remain unclear. Here, we sought to define the role of SIRT6 in BC cell metabolism and...
Uploaded on: April 14, 2023